By neutralizing IFN, anifrolumab effectively suppresses downstream proinflammatory factors and autoantibody production, demonstrating that anticytokine strategies can rebalance immune responses in autoimmune diseases [685]. The gene discussed is IFNA1; the disease is autoimmune disease.